Century Therapeutics Files 8-K
Ticker: IPSC · Form: 8-K · Filed: Apr 11, 2024 · CIK: 1850119
| Field | Detail |
|---|---|
| Company | Century Therapeutics, INC. (IPSC) |
| Form Type | 8-K |
| Filed Date | Apr 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, exhibits
TL;DR
Century Therapeutics filed an 8-K, mostly for financial docs, no big news.
AI Summary
On April 11, 2024, Century Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text. The company is incorporated in Delaware and headquartered in Philadelphia, PA.
Why It Matters
This 8-K filing indicates routine financial reporting and exhibit submissions by Century Therapeutics, Inc. without disclosing new material events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material changes or risks.
Key Numbers
- 001-40498 — SEC File Number (Identifies the company's filing with the SEC.)
- 84-2040295 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Century Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Philadelphia, Pennsylvania (location) — Principal executive offices
- April 11, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Financial Statements and Exhibits' section.
When was this 8-K report filed?
This 8-K report was filed on April 11, 2024.
What is Century Therapeutics, Inc.'s state of incorporation?
Century Therapeutics, Inc. is incorporated in Delaware.
Where are Century Therapeutics, Inc.'s principal executive offices located?
Century Therapeutics, Inc.'s principal executive offices are located at 25 North 38th Street, 11th Floor, Philadelphia, Pennsylvania, 19104.
Does this filing report any specific material events?
Based on the provided text, this filing is categorized under 'Other Events' and 'Financial Statements and Exhibits,' and does not explicitly detail any specific new material events.
Filing Stats: 456 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-04-11 14:42:28
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share IPSC Nasdaq Global Select
Filing Documents
- tm2411557d2_8k.htm (8-K) — 28KB
- tm2411557d2_ex99-1.htm (EX-99.1) — 41KB
- tm2411557d2_ex99-1img001.jpg (GRAPHIC) — 448KB
- tm2411557d2_ex99-1img002.jpg (GRAPHIC) — 673KB
- tm2411557d2_ex99-1img003.jpg (GRAPHIC) — 799KB
- tm2411557d2_ex99-1img004.jpg (GRAPHIC) — 348KB
- tm2411557d2_ex99-1img005.jpg (GRAPHIC) — 432KB
- tm2411557d2_ex99-1img006.jpg (GRAPHIC) — 305KB
- tm2411557d2_ex99-1img007.jpg (GRAPHIC) — 404KB
- tm2411557d2_ex99-1img008.jpg (GRAPHIC) — 300KB
- tm2411557d2_ex99-1img009.jpg (GRAPHIC) — 610KB
- tm2411557d2_ex99-1img010.jpg (GRAPHIC) — 297KB
- tm2411557d2_ex99-1img011.jpg (GRAPHIC) — 318KB
- tm2411557d2_ex99-1img012.jpg (GRAPHIC) — 300KB
- tm2411557d2_ex99-1img013.jpg (GRAPHIC) — 365KB
- tm2411557d2_ex99-1img014.jpg (GRAPHIC) — 281KB
- tm2411557d2_ex99-1img015.jpg (GRAPHIC) — 343KB
- tm2411557d2_ex99-1img016.jpg (GRAPHIC) — 407KB
- tm2411557d2_ex99-1img017.jpg (GRAPHIC) — 265KB
- tm2411557d2_ex99-1img018.jpg (GRAPHIC) — 276KB
- tm2411557d2_ex99-1img019.jpg (GRAPHIC) — 281KB
- tm2411557d2_ex99-1img020.jpg (GRAPHIC) — 439KB
- tm2411557d2_ex99-1img021.jpg (GRAPHIC) — 306KB
- tm2411557d2_ex99-1img022.jpg (GRAPHIC) — 464KB
- tm2411557d2_ex99-1img023.jpg (GRAPHIC) — 298KB
- tm2411557d2_ex99-1img024.jpg (GRAPHIC) — 387KB
- tm2411557d2_ex99-1img025.jpg (GRAPHIC) — 399KB
- tm2411557d2_ex99-1img026.jpg (GRAPHIC) — 518KB
- tm2411557d2_ex99-1img027.jpg (GRAPHIC) — 289KB
- tm2411557d2_ex99-1img028.jpg (GRAPHIC) — 411KB
- tm2411557d2_ex99-1img029.jpg (GRAPHIC) — 309KB
- tm2411557d2_ex99-1img030.jpg (GRAPHIC) — 282KB
- tm2411557d2_ex99-1img031.jpg (GRAPHIC) — 142KB
- tm2411557d2_ex99-1img032.jpg (GRAPHIC) — 485KB
- tm2411557d2_ex99-1img033.jpg (GRAPHIC) — 799KB
- 0001104659-24-046247.txt ( ) — 18142KB
- ipsc-20240411.xsd (EX-101.SCH) — 3KB
- ipsc-20240411_lab.xml (EX-101.LAB) — 33KB
- ipsc-20240411_pre.xml (EX-101.PRE) — 22KB
- tm2411557d2_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events On April 11, 2024, Century Therapeutics, Inc. (the "Company") updated information reflected in a slide presentation, which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 99.1 Investor Presentation of Century Therapeutics, Inc., dated April 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENTURY THERAPEUTICS, INC. By: /s/ Brent Pfeiffenberger, Pharm.D. Name: Brent Pfeiffenberger, Pharm.D. Title: President and Chief Executive Officer Date: April 11, 2024